IP Library › Granted Patent US 12,258,395
Granted Patent B2
US 12,258,395 · App. 16/973,502 · Granted Mar 25, 2025

Materials and methods for treating stress-related disorders and cancer

Inventors: Todd Eliot Golde (Gainesville, FL); Hunter S. Futch (Gainesville, FL); Brenda Dawn Moore (Gainesville, FL); Benoit Giasson (Gainesville, FL)
Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
C07K16/26A61K38/35A61K39/001144A61K47/6415A61K47/6847A61P35/00C07K16/2818A61K2039/505
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,258,395
App. No.
16/973,502
Granted
Mar 25, 2025
Kind
B2
Abstract

Disclosed herein are materials and methods for the treatment of stress-related disorders and cancer. The disclosure provides an antibody, or antigen binding fragment thereof, that specifically binds to a region of corticotropin-releasing hormone (CRH). The disclosure also provides methods of treating a disorder associated with HPA axis activation, such as a stress-related disorder or cancer, comprising administering to a subject in need thereof an antibody or antigen binding fragment thereof described herein in an amount effective to treat the disorder.

Claims (8)

1. An antibody or antigen binding fragment thereof that specifically binds to a region of corticotropin-releasing hormone (CRH), wherein the antibody or antigen binding fragment comprises a set of 6 CDRs set forth in SEQ ID NOs: 12-17.

2. The antibody or antigen binding fragment of claim 1 , comprising a heavy chain variable region comprising an amino acid sequence set forth in SEQ ID NO: 19.

3. The antibody or antigen binding fragment of claim 1 , comprising a light chain variable region comprising an amino acid sequence set forth in SEQ ID NO: 18.

4. The antibody or antigen binding fragment thereof of claim 1 , that is a monoclonal antibody.

5. The antibody or antigen binding fragment of claim 1 , that is a humanized antibody.

6. The antibody or antigen binding fragment of claim 1 , that is an IgG.

7. The antibody or antigen binding fragment of claim 1 , wherein the antigen binding fragment is a Fab fragment or an scFv.

8. The antibody or antigen binding fragment of claim 7 , wherein the scFv comprises an amino acid sequence set forth in SEQ ID NO: 22 or SEQ ID NO: 23.

Assignments (2)
CONFIRMATORY LICENSE Recorded Oct 13, 2023
From: UNIVERSITY OF FLORIDA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065238/0155 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2021
From: GOLDE, TODD ELIOT; FUTCH, HUNTER S.; MOORE, BRENDA DAWN; GIASSON, BENOIT
To: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
Reel/Frame 056542/0619 →
Continuity (4)
Provisional Application 62843677 · May 6, 2019
Provisional Application 62777572 · Dec 10, 2018
Provisional Application 62683369 · Jun 11, 2018
Related Publication 20210371514A1 · Dec 2, 2021
References Cited (88)
US 3773919A · Boswell et al. · 1973 [cited by applicant]
US 4946778A · Ladner et al. · 1990 [cited by applicant]
US 5139941A · Muzyczka et al. · 1992 [cited by applicant]
US 5225539A · Winter · 1993 [cited by applicant]
US 5236901A · Burks et al. · 1993 [cited by applicant]
US 5252479A · Srivastava · 1993 [cited by applicant]
US 5328688A · Roizman · 1994 [cited by applicant]
US 5403484A · Ladner et al. · 1995 [cited by applicant]
US 5474935A · Chatterjee et al. · 1995 [cited by applicant]
US 5545806A · Lonberg et al. · 1996 [cited by applicant]
US 5569825A · Lonberg et al. · 1996 [cited by applicant]
US 5571698A · Ladner et al. · 1996 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5585362A · Wilson et al. · 1996 [cited by applicant]
US 5622856A · Natsoulis · 1997 [cited by applicant]
US 5631237A · Dzau et al. · 1997 [cited by applicant]
US 5639641A · Pedersen et al. · 1997 [cited by applicant]
US 5658776A · Flotte et al. · 1997 [cited by applicant]
US 5661033A · Ho et al. · 1997 [cited by applicant]
US 5670488A · Gregory et al. · 1997 [cited by applicant]
US 5693509A · Cotten et al. · 1997 [cited by applicant]
US 5693761A · Queen et al. · 1997 [cited by applicant]
US 5693762A · Queen et al. · 1997 [cited by applicant]
US 5702892A · Mulligan-Kehoe · 1997 [cited by applicant]
US 5707618A · Armentano et al. · 1998 [cited by applicant]
US 5714352A · Jakobobits et al. · 1998 [cited by applicant]
US 5733790A · Potter et al. · 1998 [cited by applicant]
US 5773289A · Samulski et al. · 1998 [cited by applicant]
US 5780279A · Matthews et al. · 1998 [cited by applicant]
US 5789390A · Descamps et al. · 1998 [cited by applicant]
US 5792453A · Hammond et al. · 1998 [cited by applicant]
US 5821047A · Garrard et al. · 1998 [cited by applicant]
US 5824520A · Mulligan-Kehoe · 1998 [cited by applicant]
US 5824544A · Armentano et al. · 1998 [cited by applicant]
US 5830727A · Wang et al. · 1998 [cited by applicant]
US 5834441A · Philip et al. · 1998 [cited by applicant]
US 5837500A · Ladner et al. · 1998 [cited by applicant]
US 5849571A · Glorioso et al. · 1998 [cited by applicant]
US 5851521A · Branellec et al. · 1998 [cited by applicant]
US 5855885A · Smith et al. · 1999 [cited by applicant]
US 5856152A · Wilson et al. · 1999 [cited by applicant]
US 5858657A · Winter et al. · 1999 [cited by applicant]
US 5863541A · Samulski et al. · 1999 [cited by applicant]
US 5871907A · Winter et al. · 1999 [cited by applicant]
US 5879934A · Deluca · 1999 [cited by applicant]
US 5969108A · Mccafferty et al. · 1999 [cited by applicant]
US 6020305A · Theoharides · 2000 [cited by applicant]
US 6057098A · Buechler et al. · 2000 [cited by applicant]
US 6225447B1 · Winter et al. · 2001 [cited by applicant]
US 6265150B1 · Terstappen et al. · 2001 [cited by applicant]
US 20020197266A1 · Debinski · 2002 [cited by applicant]
CN 107043752A · 2017 [cited by applicant]
EP 0088046A2 · 1983 [cited by applicant]
EP 0133988A2 · 1985 [cited by applicant]
EP 0058481B1 · 1986 [cited by applicant]
EP 0143949B1 · 1988 [cited by applicant]
EP 0036676B2 · 1990 [cited by applicant]
EP 0239400B1 · 1994 [cited by applicant]
EP 1094072A1 · 2001 [cited by applicant]
GB 2188638A · 1987 [cited by applicant]
WO 9315722A1 · 1993 [cited by applicant]
Arranz et al., The impact of stress on tumor growth: peripheral CRF mediates tumor-promoting effects of stress, Molecular Cancer, (9)1:261 (2010). [cited by applicant]
Castro et al., The use of inclusion bodies, isolated from [cited by applicant]
Futch et al., An anti-CRF antibody suppresses the HPA axis and reverses stress-induced phenotypes, Journal of Experimental Medicine, 216(11):2479-2491 (2019). [cited by applicant]
Hagan et al., Development of a two-site immunoradiometric assay for rat/human corticotrophin-releasing factor—Application to the measurement of interleukin-1ß-stimulated production of hypothalamic CRF in vitro, Journal … [cited by applicant]
Linton et al., Corticotrophin-releasing hormone (CRH)-binding protein interference with CRH antibody binding: implications for direct CRH immunoassay, Journal of Endocrinology, 146(1):45-53 (1995). [cited by applicant]
Androulidaki et al., Corticotropin Releasing Factor promotes breast cancer cell motility and invasiveness, Mol. Cancer, 8:30 (2009). [cited by applicant]
Chothia et al., Canonical structures for the hypervariable regions of immunoglobulins, J. Mol. Biol., 196:901-917 (1987). [cited by applicant]
Chothia et al., Conformations of immunoglobulin hypervariable regions, Nature, 342:877-883 (1989). [cited by applicant]
Cote et al., Generation of human monoclonal antibodies reactive with cellular antigens, Proc. Natl. Acad. Sci. USA, 80(7):2026-2030 (1983). [cited by applicant]
Eppstein et al., Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor, Proc. Natl. Acad. Sci. USA, 82(11):3688-3692 (1985). [cited by applicant]
Hu et al., Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts, Cancer Res., 56(13):3055-3061 (1996). [cited by applicant]
International Application No. PCT/US19/36337, International Preliminary Report on Patentability, mailed Dec. 24, 2020. [cited by applicant]
International Application No. PCT/US19/36337, International Search Report and Written Opinion, mailed Oct. 2, 2019. [cited by applicant]
Karpovsky et al., Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies, J. Exp. Med., 160(6):1686-701 (1984). [cited by applicant]
Kim et al., Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1, J. Virol., 72(1):811-816 (1998). [cited by applicant]
Kohler et al., Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, 256:495-497 (1975). [cited by applicant]
Kortt et al., Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting, Biomol Eng., 18(3):95-108 (2001). [cited by applicant]
Monison et al., Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains, Proc. Natl. Acad. Sci. USA, 81(21):6851-6855 (1984). [cited by applicant]
Orlandi et al., Cloning immunoglobulin variable domains for expression by the polymerase chain reaction, Proc. Natl. Acad. Sci. USA, 86(10):3833-3837 (1989). [cited by applicant]
Perricaudet et al., Widespread long-term gene transfer to mouse skeletal muscles and heart, J. Clin. Invest., 90:626-630 (1992). [cited by applicant]
Philips et al., Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies, Int. Immunol., 27(1):39-46 (2015). [cited by applicant]
Quantin et al., Adenovirus as an expression vector in muscle cells in vivo, Proc. Natl. Acad. Sci. USA, 89(7):2581-2584 (1992). [cited by applicant]
Raadsheer et al., Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer's disease and depression, Am. J. Psychiatry, 152(9):1372-6 (1995). [cited by applicant]
Reiter et al., Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv, Protein Engine… [cited by applicant]
Structural Genomics Consortium, Protein production and purification, Nat Methods, 5(2):135-146 (2008). [cited by applicant]
Todorovska et al., Design and application of diabodies, triabodies and tetrabodies for cancer targeting, J. Immunol. Methods, 248:47-66 (2001). [cited by applicant]
Winter et al., Man-made antibodies, Nature, 349:293-299 (1991). [cited by applicant]